Search
Lacutamab
go.drugbank.com/drugs/DB15322InvestigationalLacutamab is under investigation in clinical trial NCT02593045 (Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)).
Axomadol
go.drugbank.com/drugs/DB16100InvestigationalAxomadol is under investigation in clinical trial NCT01043263 (Efficacy and Safety of EN3324 (Axomadol) in Subjects With Chronic Low Back Pain).
Synonyms: Bn-110 free baseEmpegfilgrastim
go.drugbank.com/drugs/DB16155InvestigationalEmpegfilgrastim is under investigation in clinical trial NCT01569087 (Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer).
CHIR-124
go.drugbank.com/drugs/DB06852ExperimentalCHIR-124 is a potent inhibitor of Chk1 that potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.
Tretazicar
go.drugbank.com/drugs/DB04253InvestigationalTretazicar is under investigation in clinical trial NCT00746590 (Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma).
Efzofitimod
go.drugbank.com/drugs/DB16453InvestigationalIt is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states.
Aldafermin
go.drugbank.com/drugs/DB16086InvestigationalAldafermin is under investigation in clinical trial NCT03912532 (Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center … Study in Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)).
Synonyms: (phe5>met,ser6>arg,ala8>ser,gly9>ser,his11>leu) fibroblast growth factor 19 (human fgf19) (5-194)-peptide, produced in escherichia coliPF-04620110
go.drugbank.com/drugs/DB14887InvestigationalPF-04620110 is under investigation in clinical trial NCT01146327 (A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects).
Spartalizumab
go.drugbank.com/drugs/DB14892InvestigationalSpartalizumab is under investigation in clinical trial NCT02605967 (Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma).